← All Biocardia, INC filings

Biocardia, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BCDA
Biocardia, INC
10-K: BioCardia Reports FY 2024 Results, Focuses on CardiAMP Trials and Allogeneic MSC Therapy
BioCardia, a clinical-stage company, announces its FY 2024 results, highlighting progress in its CardiAMP cell therapy trials for heart failure and chronic myocardial ischemia, as well as its allogeneic MSC therapy platform.
NASDAQ
BCDA
Biocardia, INC
10-K: BioCardia's 2023 10-K Filing: Focus on Clinical Trials and Financial Outlook
BioCardia's 2023 10-K filing highlights ongoing clinical trials for its cell therapy platforms and its financial position as a clinical-stage company.